DocMorris, the Swiss online pharmacy and telemedicine group listed on SIX, reported notable sales momentum in the second quarter, driven primarily by a jump in prescription medicine demand and a fast-growing digital services segment.
In the April-June quarter, the company's external revenue rose 15.2% in local currency to 309.7 million Swiss francs, while reported revenue climbed 16.1% to 295.4 million francs. The company highlighted that Germany was the main source of growth, with prescription (Rx) external revenue increasing 45.8%. That pace of expansion accelerated from the first quarter and represented a 17.2% sequential rise.
DocMorris said its Digital Services division - which encompasses TeleClinic, retail media and its marketplace business - delivered an 80% increase in revenue to 13.9 million francs. The group also reported an expanded active customer base, which grew by 1.1 million year-over-year to reach 12.9 million. Management attributed the customer gains to a significant uplift in new prescription medicine customers.
The company described the stronger prescription medicine trajectory as positioning DocMorris "fully on track" to achieve EBITDA breakeven during 2026. Looking ahead, DocMorris announced it will refresh its full-year 2026 guidance when it releases half-year results on Aug. 19. That update will take into account the positive impact of first-half trading and the group’s recently announced "AI-First" strategy, which targets annual cost savings of at least 15 million francs.
Operational highlights from the quarter include:
- External revenue of 309.7 million francs, up 15.2% in local currency.
- Reported revenue of 295.4 million francs, up 16.1% year-over-year.
- Prescription external revenue in Germany up 45.8% year-over-year, and up 17.2% sequentially.
- Digital Services revenue rising 80% to 13.9 million francs.
- Active customer base increased by 1.1 million to 12.9 million.
The company’s next formal update will coincide with its half-year financial report on Aug. 19, when management will publish revised guidance that incorporates first-half performance and anticipated savings from its AI-First cost program.
DocMorris’ quarterly results underscore momentum across its core pharmacy business and supplementary digital offerings, while management maintains a clear timeline for reaching EBITDA breakeven in 2026 contingent on continued execution against both revenue growth and cost-savings measures.